Avacta Group Regulatory News (AVCT)

12 September 2024

Avacta Group plc

("Avacta" or the "Company")

Notice of Results

Investor Presentation via Investor Meet Company

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, will announce its unaudited interim results on 30 September 2024 for the six months ended 30 June 2024.

Christina Coughlin, MD, PhD, Avacta's CEO, will discuss the results and the Company's operational and clinical progress via the Investor Meet Company platform on 30 September 2024 at 11:00 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 29 September 2024, 09:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:

https://www.investormeetcompany.com/avacta-group-plc/register-investor.

Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

The Company will also post its results presentation on its website at the following page: https://avacta.com/investors/documents-presentations.

-Ends-

For further information from Avacta Group plc, please contact:

About Avacta Group plc - www.avacta.com

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts